CoChat

Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct

Open access

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Background Drug-induced liver injury (DILI) is an uncommon adverse drug reaction of increasing importance to the medical community, pharmaceutical industry, regulatory agencies and the general public. Objectives The Drug-Induced Liver Injury Network (DILIN) was established to advance understanding and research into DILI by initiating a prospective registry of patients with bona fide DILI for future studies of host clinical, genetic, environmental and immunological risk factors. The DILIN was also charged with developing standardized nomenclature, terminology and causality assessment instruments. Methods Five clinical sites, a data coordinating centre and senior scientists from the National Institute of Diabetes and Digestive and Kidney Diseases initiated the DILIN prospective study in September 2004. Eligible patients are required to meet minimal laboratory or histological criteria within 6 months of DILI onset and have other competing causes of liver injury excluded. Patients in the general community setting with pre-existing HIV, hepatitis B virus or hepatitis C virus infections and/or abnormal baseline liver biochemistries are eligible for enrollment. In addition, subjects with liver injury due to herbal products are eligible to participate. Control patients without DILI are also to be recruited in the future. Results All referred subjects undergo an extensive review of available laboratory, pathology and imaging studies. Subjects who meet pre-defined eligibility criteria at the 6-month study visit are followed for 2 years to better define the natural history of chronic DILI. Causality assessment is determined by a panel of three hepatologists who independently assign a causality score ranging from 1 (definite) to 5 (unlikely) as well as a severity score ranging from 1 (mild) to 5 (fatal). During the first 3 years, 367 subjects were enrolled into the DILIN prospective study. Conclusion DILIN is a multicentre research network charged with improving our understanding of the aetiologies, risk factors and outcomes of DILI in the US. The network is meeting the targeted enrollment of ten patients per month and is developing a repository of clinical data and biological samples for future studies of DILI pathogenesis and outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2165/00002018-200932010-00005

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 6

  1. Varni, 2003, Ambul Pediatr, 3, 329, 10.1367/1539-4409(2003)003 · doi:10.1367/1539-4409(2003)003
  2. Nunez, 2005, Drug Saf, 38, 53
  3. Kleiner, 2007, Gastroenterology, 132, M1775
  4. Galan, 2005, J Clin Gastroenterol, 39, 64
  5. Mok, 2000, Clin Exp Rheumatol, 18, 363
  6. Rockey, 2007, Gastroenterology, 132, M1777

Cited by

See all 533

Metadata

Authors
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J.
Affiliations
  • University of Michigan (US)
  • University of North Carolina at Chapel Hill (US)
  • Indiana University Indianapolis (US)
  • University of California, San Francisco (US)
  • Duke Clinical Research Institute (US)
Corresponding author
Fontana, Robert J.
Venue
Drug Safety
Published
2009
Volume
32
Issue
1
Pages
55-68
ISSN
0114-5916 (ISSN-L)
OpenAlex
W2060470911
Cited by
486
References
51
Citations by year
2026: 23 · 2025: 22 · 2024: 34 · 2023: 30 · 2022: 37 · 2021: 30 · 2020: 35 · 2019: 41 · 2018: 28 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 29 · 2013: 31 · 2012: 21
FWCI
17.95
Type
journal article
Language
en
Open access
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5u01dk065211-22, 5u01dk065238-11, 5u01dk065193-05, 5u01dk065184-22)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK-065238, U01‐DK065193, U01 DK-065184, U24DK065176, U01 DK-065211, 1U01DK065238, 1U01DK065193, 1U01DK065211, 1U01DK065184, U01DK065201, U01DK065176)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
drug-induced liver injury, Drug-Induced Liver Injury Network, causality assessment, risk factors, adverse drug reactions, standardized terminology, hepatotoxicity
MeSH terms
Follow-Up Studies, Humans, Terminology as Topic, Prospective Studies, Registries, Research Design, Risk Factors, Severity of Illness Index, United States, National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct. https://app.cochat.ai/papers/10.2165/00002018-200932010-00005
The paper
Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., & Rochon, J. (2009). Drug-Induced Liver Injury Network (DILIN) Prospective Study: Rationale, Design and Conduct. Drug Safety. https://doi.org/10.2165/00002018-200932010-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.